Urine concentrations of neopterin , a marker for the activation of cellular immunity, were determined concomitantly with a large panel of hematological and immunological variables on 24 women with gynaecological cancers (12 uterine cervix, 5 endometrium, 7 ovary). There were 14 women investigated at first diagnosis of carcinoma, and 10 women were studied during follow-up (evidence of disease, only palliative treatment during the preceding three months). A statistically significant correlation was found between neopterin concentrations and number of circulating non-B lymphocytes expressing HLA-DR antigen. Neopterin concentrations, numbers of HLA-DR positive cells, and numbers of circulating leukocytes were significantly higher in women studied during follow-up, when compared with women freshly diagnosed. In contrast.
Introduction

Neopterin
(6D-erythro-[1' ,2' ,3' -trihydroxypropyl]-pterin) is produced in large amounts by human monocytes/macrophages in response to activation with interferon gamma in vitro (1) . In vivo, measurement of neopterin concentrations in body fluids, e. g., urine or serum, has been widely used as a convenient and sensitive marker for the activation of cellular immunity (2 -4).
Various authors have reported raised neopterin concentrations in urine or serum of patients with malignant tumors. Moreover, high levels of neopterin at 4) Author to whom correspondence should be addressed.
Pteridines I Vol. 2 ! 1990 / No. 1 Copyright «-) 1990 Walter de Gruyter . Berlin' New York diagnosis of cancer and/or during follow-up were shown to be significantly associated with poor prognosis (5 -10).
There is a considerable interest to show by more direct methods that raised neopterin concentrations in body fluids of patients with malignant disease are really due to immune activation phenomena. Here we report data cross-sectionally obtained on 24 women with gynaecological carcinomas, in whom urinary neopterin was measured concomitantly with a variety of hematological and immunological variables. By comparison of data from women with newly diagnosed cancer with those from women with malignant disease in a late phase, we attempted to describe immunological changes occurring during course of cancer.
Patients and Methods
Patients
Twenty-four women were included into the study who were patients at the Department of Obstetrics and Gynaecology of the University Hospital ofInnsbruck, Austria. The patients fulfilled the following enrollment criteria: histologically proven carcinoma of the uterine cervix (12 patients), of the ovary (seven patients) or of the endometrium (five patients); and the patients were not receiving any specific therapy at the time of investigation. Thus, there were 14 women in whom the malignant disease was freshly diagnosed, and 10 women who were in a late stage of their disease and were receiving only palliative therapy since at least three months. The mean age of the 14 pretherapeutic women was 64.3 yr (SD 10.5 yr) with a range from 39 to 76 yr, the 10 women with late stage disease were on average 65.3 yr old (SD 10.9 yr) with a range from 47 to 78 yr. According to the staging criteria of the International Federation of Gynaecology and Obstetrics, there were six women with stage I, eight with stage II, seven with stage III and three with stage IV. (Since the aim of this study was a first elucidation of the effect of longstanding malignant disease on neopterin and its associations with other immune parameters, and since the patients did not receive currently any tumor specific medication, the details of prior tumor specific medication of the 10 women with late disease were not analysed in detail).
Immunophenotyping of peripheral blood mononuclear cells ( PBMC)
These analyses were performed at the Department of Internal Medicine of the University of Innsbruck. Venous blood was collected into 20 mL syringes containing heparin as anticoagulant. PBMC were obtained using a density separation (density 1.077 g/cm 3 ) (Percoll' Pharmacia, Uppsala, Sweden) and adjusted to a concentration of 10 7 cells per mL. For the immunophenotyping an indirect immunofluorescence assay with FITC-conjugated goat anti-mouse immunoglobulin antibody was performed. The immunofluorescence analyses were made using a fluorescence activated cell sorter (FACStar, BectonDickinson).
For the present investigation, only the lymphocyte fraction of peripheral blood cells was evaluated. To obtain the number of immunologically relevant HLA-DR + lymphocytes, the number of B lymphocytes as assessed with the antibody B4 (CD19) was subtracted from the entire number of positive cells. Thus, " HLA-DR + lymphocytes" in this paper always refers to this corrected number.
. Determination of neopterin
Concomitantly with collection of blood, first morning urine specimens were obtained from the patients. These were protected from daylight using a tin-foil and stored at -20°C until analysis. The determination of neopterin was performed at the Institute for Medical Chemistry and Biochemistry of the University of Innsbruck. For the analysis, an optimized and automated high performance liquid chromatography technique on reversed phase was used which has been described earlier (3) . Neopterin was quantitated by its native fluorescence at 353 nm excitation and 438 nm emission wavelengths. To correct for physiological variations of urine concentrations, values were related to creatinine which was determined in the same chromatographic run, using its UV absorption at 235 nm. Neopterin concentrations are therefore given in ~mol per mol creatinine.
Normal values
In order to put the observed neopterin data and the results of the immunologic variables in perspective, we report the normal ranges used. For urinary neopterin, the upper limit of normal is slightly age-and sex-dependent and varies between 230 to 250 ~mol neopterin per mol creatinine for women of the age categories under interest. The normal ranges for the immunological variables are: number of CD3 + cells, 800 to 2500 per ~L ; number of CD4 + cells, 430 to 1200 per ilL; number of CD8 + cells, 180 to 870 per ~L; CD4 + /CD8 + T cell ratio, 1 to 2.3 ; percentage of CD16+ cells, 4 to 26% ; percentage of CD19+ cells, 4 to 23 %.
Statistical procedures
Due to the preliminary character of the study, Pvalues below 0.10 were assumed to indicate "statistical significance". Statistical tests used were the MannWhitney U-test for comparison of data obtained in pretherapeutic women vs late stage women, linear correlation analysis and Spearman rank correlation analysis. Table 1 summarizes the observations. As can be seen from the selected percentiles shown, for several variables the distributions were distinctly asymmetric.
Results
Since it was the aim of the study to analyse possible effects of longstanding malignancy on immune parameters, data obtained on patients freshly diagnnsed were compared with those obtained on women with long-standing disease by the Mann-Whitney test. The results are shown in Figure 1 (variables for which the level of statistical significance exceeded 0.10 are not shown). Two groups of variables were seen: neopterin concentrations, numbers of HLA-DR + non-B cells and numbers of leukocytes were significantly higher in women with long-standing disease than in patients at primary diagnosis. In contrast, numbers of total and lymphocyte subgroups positive for CD4 and CD3 were significantly lower in women with long-standing disease.
The data were further analysed by correlation analysis. By linear correlation analysis, neopterin showed the strongest correlation with the number of HLA- In the center of each box, the star indicates the median value, the lower and upper limits of the box denote the 25th and 75th percentiles, and the vertical lines indicate the range of observations. For units, see Table 1 .
DR + cells (r = .638; P = 0.0005). Several other variables were also significantly correlated with neopterin (P < .10); these were in order to decreasing strength of correlation, numbers of thrombocytes (r = .408, P = .047), of CD3 + cells (r = -.377, P = .069) and of CD4 + cells (r = -.363 , P = .081). Slightly different results were obtained by Spearman's rank corre- Percentile  value  25th  50th  75th   151  109  119  129  13400  5800  6400  8200  4154  1060  1700  2330  1005  365  515  645  513  222  288  329  1146  184  287  741   3115  655  955  1650  2450  465  620  1100  708  260  410  560  1083  90  167  253  390  111  169 
M aximum
Discussion
Raised concentrations of neopterin are frequently reported in patients with malignancies (3). The finding that this substance is produced by interferon gamma activated human monocytes/macrophages (1) but not by tumor cells themselves pointed to a preactivation state of cell-mediated immunity in cancer patients. The consistent observation by various research groups of a significant association of high neopterin concentrations and poor prognosis (5 -10) is of particular interest not only for patient's management but also for a better founded immunobiological understanding of the interactions taking place between the immune system and a growing tumor.
Our results contribute to this growing body of evidence for the presence of immune activation in cancer patients. Whereas the numbers of circulating lymphocytes were lower in women wi th long-standing disease than in those studied pre therapeutically, the concentrations of neopterin in urine and the number of non-B lymphocytes expressing HLA-DR antigen and blood cells were significantly higher. Neopterin and number of HLA-DR I non-B lymphocytes, both being indicators of immune activation and very likely of endogenous interferon gamma production, were significantly and positively correlated with each other.
Our data, and previous data on neopterin in cancer patients, indicate that certain immune mechanisms are activated. Indeed, this reasoning is strongly supported by observations in patients with hematological neoplasias showing significantly higher concentrations of endogenous interferon gamma and a significant and positive correlation between interferon gamma and neopterin levels (11) . Neopterin increases do not, however, provide information whether or not the immune response can eventually eliminate the source of immune activation, e. g., tumor cells.
It is well known for a long time that patients with malignant tumors show diminished responsiveness against recall-antigens, and that immune cells derived from these patients are incapable to respond adequately against antigenic or mitogenic stimuli in vitro. Also, in vitro production of interferon gamma by T cells from cancer patients is usually decreased. Thus, there appears to exist an inverse relationship between endogenous interferon gamma production which appears to he raised and the reduced capacity of in vitro production of this Iymphokine in response to antigenic stimulation. We suggest that mechanisms induced by persistently activated immune mechanisms and particularly persistent cytokine production may contribute to immunodeficiency: It is known that immune response to antigenic stimulation requires an appropriate amount of interferon gamma (12) (13) (14) and interleukin 2 (15 , 16) . Both too low and too high doses inhibit development of a proper immune response. The first possibility (too low) is suggested by the observation that anti-interferon gamma antibodies interfere with alloantigen-or tumor antigen-driven immune response (12, 13, 15) . The second situation (too high) is compatible with data by our group showing that simultaneous stimulation of human peripheral blood mononuclear cells with purified protein derivative (PPD) of mycobacteria and exposure to high concentration of interferon gamma diminishes subsequent response to PPD but not to interleukin-2 (17) . Interleukin-2 is required for the autoerine proliferation of T cells, but interferon gamma is synthesized by T cells independently of proliferation (18) . Thus, antigenic stimulation may induce production and release of interferon gamma while later steps of T cell activation and particularly interleukin-2 synthesis may be inhibited.
Besides the consistent notion of high neopterin concentrations in patients with malignant tumors, a strong argument for the presence of immune activation are our findings on the increase of the number of HLA-DR 4 non-B cells which is significantly associated with an increase of neopterin levels. Much evidence has been accrued to indicate that interferon gamma is able to regulate class II histocompatibility antigen expression on many different cell types, including macro phages (1 9 -21).
Besides these effects, persistent immune activation could also be at least partly responsible for some of the other changes in immune parameters that have been observed in thi s study. For example, cytokines may affect the expression of erythroid progenitors and possibly other hematopoietic precursors (22) . This may be partly the cause for, e. g., the decrease of total lymphocytes a nd lymphocyte subsets . This may be true even for variables for which we were unable to detect a significant correlation with neopterin, because the effects may be small and masked by other causes: looking at the average values, our results would be compatible with such effects.
In sum, the results of our study which of course can be regarded only as preliminary, support the view that in patients with active malignant disease early events of cellular immune mechanisms may be activated. The positive correlation between neopterin concentrations and numbers of HLA-DR + cells renders substantial weight to the conclusions drawn from earlier studies that raised neopterin concentrations in tumor patients are not a product of the tumor cells. but rather reflect activation of certain cellular immune mechanisms.
